年度因弗利西马布治疗后的监测 治疗后的优化
Natsuki Ishida1, Ken Sugimoto2
1First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan. ma03006@hama-med.ac.jp.
在第14周,infliximab (IFX) 的最低水平超过3μg/mL,预测炎症性肠病 (IBD) 患者的持续治疗水平. 对于稳定的患者,每年监测可能足够,优化IFX治疗.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 因弗利西马布 (IFX) 是一种关键的TNF-α抑制剂,用于炎症性肠病 (IBD).
- 治疗失败很常见,通常是由于IFX低谷值 (TLs) 或抗药抗体.
- 治疗药物监测 (TDM) 对于优化IFX治疗至关重要.
研究的目的:
- 确定IFX治疗IBD患者的TDM最佳间隔.
- 根据早期TDM结果评估IFX治疗水平的长期稳定性.
主要方法:
- 在接受IFX的228名IBD患者的长度研究.
- 治疗药物监测 (TDM) 大约每两个月进行一次.
- 对IFX最低水平 (TLs) 和抗药抗体的分析.
主要成果:
- 85%的IFXTLs>3μg/mL的患者在第14周保持了治疗水平超过13个月.
- 抗药抗体主要在IFX水平下降后被检测出来.
- 在IFX治疗的稳定IBD患者中,每年TDM可能足够.
结论:
- 早期的IFX低谷值可以预测长期治疗稳定性.
- 防止IFXTLs下降至关重要,以避免抗药抗体的形成.
- 个性化的TDM策略,结合临床监测,可以提高IFX治疗IBD的有效性.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Myocarditis IV: Nursing Management
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Ulcerative Colitis in IBD
